Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced multiple presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30 – October 3, 2022 at McCormick Place Convention Center in Chicago, IL.

“We have a big presence at AAO this year with many presentations discussing product candidates across multiple ophthalmic indications, with an emphasis on retina,” said Rabia Gurses Ozden, MD, Chief Medical Officer of Ocular Therapeutix. “Most notably, we anticipate presenting 28-week data from our U.S. Phase 1 trial of OTX-TKI for the treatment of Wet AMD in a late breaker session on Friday afternoon. We will also be making two ePoster presentations on the OTX-TKI program as well as sharing real-world data updates on DEXTENZA.”

Eyecelerator @ AAO 2022 Retina Showcase Presentation:

• Session Title: Presenting Company Showcase: Retina, Therapeutics, and Technology + Devices
  
  Presentation Date/Times: Thursday, September 29, 2022, 2:00 – 2:05 PM CDT
  
  Location: McCormick Place Convention Center
  
  Presentation type: Podium Presentation
  
  Presenter: Peter K. Kaiser, MD

Retina Subspecialty Day Presentation:

• Title: Interim Safety and Efficacy Data from a Phase 1 Clinical Trial of Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Wet AMD Subjects
  
  Session Title: Late Breaking Developments, Part I (RET09)
  
  Presentation Date/Times: Friday, September 30, 2022, 3:29-3:34 PM CDT
  
  Location: Arie Crown
  
  Presentation type: Podium Presentation
  
  Presenter: Dilsher S. Dhoot, MD

Poster Theater Presentation:

• Title: Real-World Safety Analysis of an Intracanalicular Dexamethasone Insert Using the Academy’s IRIS® Registry
  
  Session Title: Cataract (PT01)
  
  Presentation Date/Times: Saturday, October 1, 2022, 9:40-9:50 AM CDT
  
  Location: Hall A Poster Theater and Lounge
  
  Presentation type: Poster Theatre
  
  Presenter: Robert T. Chang, MD

ePosters:

• Title: Real-World Patient Demographics and Clinical Characteristics of an Intracanalicular Dexamethasone Insert Using the Academy’s IRIS® Registry
  
  Session Title: Cataract
  
  Viewing Date/Times: Tuesday, September 27, 2022 starting at 9:00 AM CDT
  
  Presentation type: ePoster (PO021)
  
  Presenter: Michael Mbagwu, MD

• Title: Interim 28-weeks Data from a Phase 1 US Study of Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Previously Treated Wet AMD Subjects
  
  Session Title: Retina, Vitreous
  
  Viewing Date/Times: Friday, September 30, 2022 starting at 5:00 PM CDT
  
  Presentation type: ePoster (PO359)
  
  Presenter: Arshad M. Khanani, MD

• Title: Australia-based Phase 1 Trial of a Novel, Hydrogel-based, Intravitreal Axitinib Implant for the Treatment of Neovascular Age-related Macular Degeneration
  
  Session Title: Retina, Vitreous
  
  Viewing Date/Times: Friday, September 30, 2022 starting at 5:00 PM CDT
  
  Presentation type: ePoster (PO360)
  
  Presenter: Andrew A. Moshfeghi, MD

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.

Forward Looking Statements

Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company’s product candidates; the development and regulatory status of the Company’s product candidates, such as the Company’s development of and prospects for approvability of OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, OTX-TKI for the treatment of retinal diseases including wet AMD, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI for the chronic treatment of dry eye disease; the Company’s plans to advance the development of its product candidates or preclinical programs; the ongoing development of the Company’s extended-delivery hydrogel depot technology; the potential utility of any of the Company’s product candidates; the size of potential markets for the Company’s product candidates; the potential benefits and future operations of Company collaborations, including any potential future costs or payments thereunder; projected net product revenue, in-market sales and other financial and operational metrics of DEXTENZA and ReSure Sealant; the sufficiency of the Company’s cash resources; the Company’s anticipated participation in future presentations and medical conferences; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to successfully develop and commercialize products for the ophthalmology office setting, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, whether clinical trial data such as the data reported in this release will be indicative of the results of subsequent clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s ability to enter into and perform its obligations under collaborations and the performance of its collaborators under such collaborations, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the Company’s ability to meet supply demands, the Company’s ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company’s revenues and relevant regulatory authorities’ operations, any additional financing needs, the Company’s ability to recruit and retain key personnel, and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contacts

Investors
Ocular Therapeutix

Donald Notman

Chief Financial Officer

[email protected]

or

Westwicke, an ICR Company

Chris Brinzey, 339-970-2843

Managing Director

[email protected]

Media
Ocular Therapeutix

Scott Corning

Senior Vice President, Commercial

[email protected]